Reviewing Eiger BioPharmaceuticals (EIGR) & Genocea Biosciences (GNCA)

Eiger BioPharmaceuticals (NASDAQ: EIGR) and Genocea Biosciences (NASDAQ:GNCA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, earnings, profitability, risk and institutional ownership.

Profitability

This table compares Eiger BioPharmaceuticals and Genocea Biosciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Eiger BioPharmaceuticals N/A -128.94% -88.88%
Genocea Biosciences N/A -235.87% -125.53%

Valuation & Earnings

This table compares Eiger BioPharmaceuticals and Genocea Biosciences’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Eiger BioPharmaceuticals N/A N/A -$46.28 million ($5.69) -2.39
Genocea Biosciences N/A N/A -$54.72 million ($2.03) -0.84

Eiger BioPharmaceuticals is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Eiger BioPharmaceuticals has a beta of 2.54, suggesting that its share price is 154% more volatile than the S&P 500. Comparatively, Genocea Biosciences has a beta of 2.05, suggesting that its share price is 105% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Eiger BioPharmaceuticals and Genocea Biosciences, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eiger BioPharmaceuticals 0 0 4 0 3.00
Genocea Biosciences 0 2 3 0 2.60

Eiger BioPharmaceuticals currently has a consensus target price of $32.60, indicating a potential upside of 139.71%. Genocea Biosciences has a consensus target price of $11.90, indicating a potential upside of 600.00%. Given Genocea Biosciences’ higher probable upside, analysts plainly believe Genocea Biosciences is more favorable than Eiger BioPharmaceuticals.

Insider and Institutional Ownership

59.9% of Eiger BioPharmaceuticals shares are held by institutional investors. Comparatively, 59.3% of Genocea Biosciences shares are held by institutional investors. 28.8% of Eiger BioPharmaceuticals shares are held by insiders. Comparatively, 6.7% of Genocea Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Eiger BioPharmaceuticals beats Genocea Biosciences on 8 of the 10 factors compared between the two stocks.

Eiger BioPharmaceuticals Company Profile

Eiger BioPharmaceuticals, Inc., formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema. Lonafarnib is an orally active inhibitor of farnesyl transferase that inhibits the prenylation step of HDV replication inside liver cells and blocks the ability of the virus to multiply. It is conducting over three Phase II clinical trials, which include LOnafarnib With and without Ritonavir (LOWR) HDV-2 (Ankara, Turkey), LOWR HDV-3 (NIH) and LOWR HDV-4 (Hannover, Germany). Exendin is in Phase II clinical studies for the treatment of hypoglycemia associated with bariatric surgery. Ubenimex is in Phase II clinical studies for the treatment of PAH and lymphedema.

Genocea Biosciences Company Profile

Genocea Biosciences, Inc., is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company has one product candidate in Phase III clinical development, GEN-003, an immunotherapy for the treatment of genital herpes. It also has a pre-clinical immuno-oncology program focused on personalized cancer vaccines (GEN-009). The GEN-009 program leverages ATLAS to identify patient neoantigens, or newly formed antigens unique to each patient, that are associated with that individual’s tumor.

Receive News & Ratings for Eiger BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger BioPharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply